5-（4-甲酰基苯基）-2-噻吩甲酸乙酯 | 850074-81-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-（4-甲酰基苯基）-2-噻吩甲酸乙酯
• 英文名称: ethyl 5-(4-formylphenyl)thiophene-2-carboxylate
• 英文别名: 5-(4-formyl-phenyl)-thiophene-2-carboxylic acid ethyl ester；Ethyl 5-(4-formylphenyl)-2-thiophenecarboxylate
• CAS: 850074-81-6
• 化学式: C₁₄H₁₂O₃S
• 分子量: 260.313
• InChiKey: FLDQOSNQMGRVAL-UHFFFAOYSA-N

物化性质

• 熔点：
  89-91°

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  5-溴噻吩-2-甲酸乙酯 、 对溴苯甲醛 在 三甲基氯硅烷 、 氢化铝 、 lithium chloride 、 lead(II) chloride 、 zinc diacetate 、 [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl) palladium(II) dichloride 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 以92%的产率得到5-（4-甲酰基苯基）-2-噻吩甲酸乙酯
  参考文献：
  名称：

  铝直接插入不饱和卤化物制备功能化有机铝

  摘要：

  多功能有机金属化合物的制备在有机合成中很重要，因为这些试剂是非常流行的亲核试剂。通过直接插入铝粉制备官能化铝试剂通常是不可能的。由于铝的价格比镁低（它是价格的一半）、这种金属的低毒性以及所得有机铝试剂的化学选择性，这种反应将特别重要。我们现在发现，通过添加催化量的选定金属氯化物（TiCl 4、BiCl 3、InCl 3或 PbCl 2) 在 LiCl 存在下，铝粉在温和条件下嵌入各种不饱和碘化物和溴化物中。这些新的有机铝试剂经历了顺利的 Pd 催化的交叉偶联和酰化反应，以及铜催化的烯丙基取代，为制药和材料科学应用提供了各种有趣的产品。

  DOI：

  10.1038/nchem.590

文献信息

• Thiophene and Benzothiophene Hydroxamic Acid Derivatives
  申请人：Miller A. Thomas

  公开号：US20070213392A1

  公开（公告）日：2007-09-13

  The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型的羟胺酸衍生物，其具有苯并噻吩或噻吩骨架。这些羟胺酸化合物可用于治疗癌症。这些羟胺酸化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物对于治疗具有肿瘤细胞增殖特征的患者是有用的。本发明的化合物还适用于预防和治疗TRX介导的疾病，例如自身免疫性、过敏性和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，例如神经退行性疾病。本发明还提供了包含羟胺酸衍生物的药物组合物和这些药物组合物的安全剂量方案，其易于遵循，并且在体内产生治疗有效量的羟胺酸衍生物。
• THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES
  申请人：Aton Pharma, Inc.

  公开号：EP1677731A2

  公开（公告）日：2006-07-12
• EP1677731A4
  申请人：——

  公开号：EP1677731A4

  公开（公告）日：2009-05-06
• US7935724B2
  申请人：——

  公开号：US7935724B2

  公开（公告）日：2011-05-03
• [EN] THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES<br/>[FR] DERIVES THIOPHENE ET BENZOTHIOPHENE D'ACIDE HYDROXAMIQUE
  申请人：ATON PHARMA INC

  公开号：WO2005034880A2

  公开（公告）日：2005-04-21

  The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases, The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.